Table 1.
General cohort characteristics
| All JSpA (N = 223) |
ERA (N = 138) |
PsA (N = 41) |
UA (N = 30) |
IBD-A (N = 14) |
p-value* | |
|---|---|---|---|---|---|---|
| Males | 111/223 (50%) | 81/138 (59%) | 8/41 (20%) | 16/30 (53%) | 6/14 (43%) | 0.000 |
| HLA-B27+ ** | 75/200 (38%) | 61/132 (46%) | 4/34 (12%) | 9/26 (35%) | 1/8 (12%) | 0.001 |
| Uveitis | 24/223 (11%) | 18/138 (13%) | 3/41 (7%) | 2/30 (7%) | 1/8 (7%) | 0.735 |
| HLA-B27+ U † | 10/22 (45%) | 8/18 (44%) | 0/2 (0%) | 1/1 (100%) | 1/1 (100%) | 0.330 |
| Symptomatic-U | 19/24 (79%) | 15/18 (83%) | 2/3 (67%) | 1/2 (50%) | 1/1 (100%) | 0.438 |
ERA Enthesitis-related arthritis, PsA psoriatic juvenile idiopathic arthritis, UA undifferentiated juvenile idiopathic arthritis, IBD-A arthropathies associated with inflammatory bowel disease, JSpA juvenile spondyloarthritis, N number of patients. HLA-B27 + -U HLA-B27 + -Uveitis. Symptomatic-U Symptomatic-Uveitis. * p value for Fischer’s exact test comparing distribution between JSpA subcohorts. **HLA-B27 status not available for 23 subjects – 6 ERA, 7 PsA, 4 UA, and 6 IBD-A. †Denominator is number of uveitis patients with HLA-B27 status known